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Ovarian cancer metastasizes via exfoliation of free-ﬂoating cells and multicellular aggregates from the primary tumor to the
peritoneal cavity. A key event in EOC metastasis is disruption of cell-cell contacts via modulation of intercellular junctional
components including cadherins. Ascites is rich in lysophosphatidic acid (LPA), a bioactive lipid that may promote early events
in ovarian cancer dissemination. The objective of this paper was to assess the eﬀect of LPA on E-cadherin junctional integrity.
We report a loss of junctional E-cadherin in OVCAR3, OVCA429, and OVCA433 cells exposed to LPA. LPA-induced loss of E-
cadherin was concentration and time dependent. LPA increased MMP-9 expression and promoted MMP-9-catalyzed E-cadherin
ectodomain shedding. Blocking LPA receptor signaling inhibited MMP-9 expression and restored junctional E-cadherin staining.
LPA-treated cells demonstrated a signiﬁcant decrease in epithelial cohesion. Together these data support a model wherein LPA
induces MMP-9 expression and MMP-9-catalyzed E-cadherin ectodomain shedding, resulting in loss of E-cadherin junctional
integrity and epithelial cohesion, facilitating metastatic dissemination of ovarian cancer cells.
1.Introduction
Epithelial ovarian cancer (EOC) is the leading cause of
death from gynecologic malignancy in the United States. In
2010, approximately 21,880 women were newly diagnosed
with EOC and 13,850 women died from complications due
to disseminated intraperitoneal metastasis [1]. Clinically,
tumors often involve the ovary and omentum, with diﬀuse,
multifocal intraperitoneal metastases and malignant ascites.
As 75% of women with EOC are initially diagnosed with
previously disseminated intra-abdominal disease, a more
detailed understanding of factors that promote successful
metastasis can ultimately improve patient survival.
I nw o m e nwi t ha d v a n c e dE OC ,o b s t r u c t i o no fp e ri t o n e a l
lymphatics together with enhanced vascular permeability
results in accumulation of malignant ascites, and the pres-
ence of ascites is an adverse prognostic factor [1–4]. Ascites
is comprised of >200 proteins, tumor and inﬂammatory
cells, and cytokines. A major bioactive component of EOC
ascites is the lipid lysophosphatidic acid (LPA). Elevated LPA
levels (up to >80μM) are detectable in 98% of patients with
EOC, including 90% of patients with stage I disease [5–10].
Multiple studies have shown that LPA contributes to tumor
development, progression, and metastasis through binding
to a subfamily of G protein-coupled receptors termed LPA
receptors (LPAR), thereby eﬀecting expression of proteases
and growth factors and modulating migration of a variety
of cells [11–19]. In EOC, treatment with LPA in vitro
results in an enhanced metastatic phenotype, characterized
by increased proteolytic activity, stimulation of motility, and2 Journal of Oncology
more aggressive invasive behavior [11, 12, 20, 21]. LPA also
enhances adherens junction dissolution and colony dispersal
and promotes epithelial-mesenchymal transition [13, 22].
Primary diﬀerentiated EOC display abundant expression of
the cell-cell junctional protein E-cadherin; however, reduced
E-cadherin staining is found in late-stage carcinomas and
data suggest that loss of E-cadherin expression or function is
a factor in EOC progression from well-diﬀerentiated lesions
to poorly diﬀerentiated tumors and metastases [2–4]. As
matrix metalloproteinases (MMPs) are implicated in E-
cadherin ectodomain shedding [23–26] and LPA is linked
to altered MMP expression [12–14], the current study was
designed to evaluate a potential functional link between
LPA, posttranslational regulation of E-cadherin function,
and epithelial cohesion in EOC.
2.MaterialsandMethods
2.1. Cell Culture. OVCA429 and OVCA433 cells, generously
provided by Dr. Robert Bast (M. D. Anderson Cancer
Center, Houston, TX), were maintained in MEM, 10%
fetal bovine serum, penicillin/streptomycin, amphotericin B,
nonessential amino acids, and sodium pyruvate at 37◦Ci n
5% CO2. OVCAR-3 cells were maintained in RPMI 1640
(American Type Culture Collection, Manassas, VA), 20%
fetal bovine serum, penicillin/streptomycin, amphotericin B,
nonessentialaminoacids,sodiumpyruvate,andinsulinfrom
bovine pancreas (10mg/L) at 37◦Ci n5 %C O 2.
2.2.Materials. LyophilizedLPAwaspurchasedfromCayman
Chemical (Ann Arbor, MI) and reconstituted in dH2O
at 2mM. LPA receptor inhibitor (LPARI), Ki16425, was
purchased from Cayman Chemical (Ann Arbor, MI). The
Ki of the inhibitor for LPA1−3 receptors is 0.3–6μM, with
a working concentration of 10μMs u ﬃcient to block LPAR
function[27].TheproteaseinhibitorsuPAStopandGM6001
were purchased from American Diagnostica Inc. (Stamford,
CT) and Chemicon (Temecula, CA), respectively. Function-
blocking anti-MMP-9 antibody was purchased from Cal-
biochem (Darmstadt, Germany), and the E-cadherin anti-
body hecd-1 was purchased from Calbiochem, Darmstadt,
Germany or Zymed, San Francisco, CA.
2.3. Immunoprecipitation and Western Blot Analysis. Cells
were subcultured in six-well plates to 70% conﬂuence. After
1 day, cells were serum starved overnight in the appropriate
medium. In some experiments, cells were pretreated with
inhibitor (or equivalent concentrations of DMSO) for 1.5
to 3 hours in serum-free media. Cells were then treated
with LPA for 18–24 hours before lysis in modiﬁed radioim-
munoprecipitation assay lysis buﬀer (mRIPA; 50mmol/L
Tris pH 7.5, 150mmol/L NaCl, 0.1% SDS, 1% Triton X-100,
5mmol/L EDTA). Protein concentrations of the resulting
lysates were determined using the Bio-Rad (Hercules, CA)
protein assay. Lysates (ranging from 30 to 70μg, as indi-
cated) were electrophoresed on an 8% SDS-polyacrylamide
gel, electroblotted to a polyvinylidene diﬂuoride (PVDF)
membrane [28], and blocked in 5% milk/TBS-T (25mmol/L
Tris pH 7.5, 150mmol/L NaCl, 0.1% Tween 20) or 3%
bovine serum albumin/TBS-T at room temperature for 1
to 3 hours. Blots were incubated overnight with 1:1,000
dilution of the primary antibody. The immunoreactive
bands were visualized using peroxidase-conjugated anti-
mouse or rabbit immunoglobulin G (1:5,000 in 3% bovine
serum albumin/TBS-T) and enhanced chemiluminescence.
To evaluate loading controls, blots were stripped of primary
antibody using a low-pH buﬀer (400mmol/L glycine pH
2.5), blocked again in 3% bovine serum albumin/TBS-
T, and reprobed with primary antibody. Western bands
were quantiﬁed by densitometric quantitation. Results were
normalized against the densitometric reading for untreated
cells.
2.4. Gelatin Zymography. Serum-free conditioned medium
was resolved using gelatin-containing SDS-polyacrylamide
gels, followed by washing with 2.5% Triton X100 and
incubation in zymography buﬀer (20mM glycine/10mM
calcium chloride/1μM zinc chloride) at 37 degrees Celsius
for 24–48 hours. Gels were stained with Coomassie blue
(45% methanol, 3g/L Coomassie Brilliant Blue, and 10%
acetic acid in dH2O), and destained in acetic acid solution
(10%aceticacidand15%methanolindH2O).Underserum-
free conditions, MMP-9 is detected in the proenzyme form
[28].
2.5. Immunoﬂuorescence Microscopy. Cells were subcultured
on glass coverslips in six-well plates to 80% conﬂuence. Fol-
lowing overnight serum-starvation in appropriate medium,
c e l l sw e r et r e a t e dw i t hL P A( 1 – 8 0μM) for 18–24 hours. In
some experiments, cells were pretreated prior to addition of
LPA with inhibitor (or equivalent concentrations of DMSO)
for 1.5 to 3 hours (GM6001-MMP inhibitor, Chemicon,
25μM; Ki16425-LPA receptor inhibitor, Cayman Chemical,
40μM; uPA Stop-uPA inhibitor, American Diagnostica,
2.5μM ) .C e l l sw e r eﬁ x e di n4 %P F Af o r2 0m i n u t e s
at room temperature, followed by immunostaining with
anti-E-cadherin (hecd-1 clone, Zymed, San Francisco, CA;
1:300) and Alexa-Fluor 488-conjugated secondary antibody
(1:500). Fluorescence microscopy was performed using an
Olympus IX-81 spinning disc confocal microscope. Semi-
quantitative analysis of E-cadherin junctional integrity was
determined by counting a minimum of 12 ﬁelds per
treatment (at least 100 cells overall) and scoring as positive
the number of cells with two remaining ﬂuorescent cell-cell
borders.
2.6. Dispase-Based Dissociation Assay. To monitor relative
changes in epithelial cohesion, dispase-based dissociation
assays were performed as previously described [29]. Brieﬂy,
cells were subcultured (triplicate per condition) in 60-
millimeter dishes to 80% conﬂuence in MEM. Cultures were
washed twice in PBS before being incubated with 2mL
dispase in DMEM/F12 (Stem Cell Technologies, Vancou-
ver, British Columbia, Canada) until the cell-cell cohesive
monolayer detached from the culture plate. Subsequently,
the detached cell monolayer was washed in PBS, transferredJournal of Oncology 3
OVCA433 OVCA429 OVCAR3
C
o
n
t
r
o
l
L
P
A
 
2
0
 
µ
M
(a)
0 LPA 1 µM LPA 3 µM LPA
10 µM LPA 30 µM LPA 80 µM LPA
(b)
0 2 04 06 08 0
0
20
40
60
80
100
P
o
s
i
t
i
v
e
 
E
-
c
a
d
h
e
r
i
n
 
s
t
a
i
n
i
n
g
 
(
%
)
[LPA] (µM)
(c)
Figure 1: LPA induces E-cadherin junction disruption in EOC cells. (a) Conﬂuent monolayers of OVCA433, OVCA429, or OVCAR3 cells,
as indicated, were treated with LPA (20μM) for 18–24 hours and processed for immunoﬂuorescence staining for E-cadherin using anti-E-
cadherin ectodomain antibody (1:300) and Alexa Fluor 488-conjugated secondary antibody (1:500; green). Blue-DAPI-stained nuclei. (b)
To evaluate the dose-dependence of LPA-induced junction loss, OVCA429 cells were treated with LPA at the concentrations indicated for
24 hours and processed for E-cadherin immunoﬂuorescence (green) as described in (a) above. Blue-DAPI-stained nuclei. (c) Junction loss
was quantiﬁed by counting the number of cells/ﬁeld with two remaining E-cadherin immunostained borders in a minimum of 5 ﬁelds per
treatment (at least 100 cells).
to a 15mL conical tube, and subjected to 50 inversion cycles
on a bench-top rocker. All cell fragments were placed into
tissue culture dishes and fragment number enumerated by
light microscopy. The assay was repeated twice and analyzed
statistically by Student’s t-test.
3. Results
Primary EOC cells express abundant E-cadherin; however,
E-cadherin staining in metastatic lesions is less prevalent
[2, 3]. To evaluate a potential posttranslational mechanism
for control of E-cadherin function, the eﬀect of LPA on
E-cadherin junctional integrity was evaluated. Treatment
of OVCA 429, OVCA433, or OVCAR3 cells with LPA
(20μM) resulted in a loss of junctional E-cadherin staining
(Figure 1(a)). Detectable loss of E-cadherin staining was
present as early as 2 hours (not shown) and was correlated
with LPA concentration (Figure 1(b)) .L P Al e v e l sa sl o w
as 1μM induced signiﬁcant loss of junctional E-cadherin
(Figures 1(b) and 1(c)). Although it was previously demon-
strated that inhibition of the activity of urinary type
plasminogen activator (uPA) could block LPA-induced E-
cadherin junction loss [30], incubation of EOC cells with
LPA in the presence of the inhibitor uPA-Stop did not result
in maintenance of junctional integrity (Figure 2).
LPA increases MMP-9 mRNA expression in breast ade-
nocarcinoma cells [31], and we have recently demonstrated
that MMP-9 catalyzes E-cadherin ectodomain shedding
in EOC cells [24, 28]. To evaluate whether the observed
decrease in E-cadherin junctional staining may result from
MMP-9-catalyzed E-cadherin ectodomain shedding, cells
were incubated with LPA overnight, and conditioned media
were subjected to immunoprecipitation using E-cadherin
ectodomain-speciﬁc antibodies followed by Western blot-
ting. Signiﬁcantly increased shedding of the E-cadherin
ectodomain was observed following LPA treatment (Figures
3(a)–3(d)). To assess the potential involvement of MMP(s)4 Journal of Oncology
Control +LPA +LPA, +DMSO
+LPA, +uPA stop +uPA stop 2◦ Ab only
Figure 2: Inhibition of uPA activity does not prevent LPA-induced E-cadherin junction disruption. OVCA429 cells were treated with or
without LPA (30μM), as indicated, for 18 hours in the presence or absence of the uPA inhibitor designated uPA Stop (2.5μM), as indicated
and processed for immunoﬂuorescence staining for E-cadherin using anti-E-cadherin ectodomain antibody (1:300) and Alexa Fluor 488-
conjugated secondary antibody (1:500; green). Blue-DAPI-stained nuclei.
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Figure 3: LPA induces MMP-dependent E-cadherin ectodomain shedding. (a, b) OVCA429 or (c, d) OVCA433 cells were treated with LPA
(30μM) in the presence or absence of the broad-spectrum MMP inhibitor GM6001 (25μM) as indicated for 24 hours. Conditioned media
were subjected to immunoprecipitation with anti-E-cadherin antibodies, and precipitates were western blotted with a second E-cadherin
antibody (Zymed, 1:1,000) followed by peroxidase-conjugated secondary antibody (1:5,000) and enhanced chemiluminescence detection.
Panels (b, d) show densitometric quantitation of replicate western blots.Journal of Oncology 5
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Figure 4: LPA induces MMP-9-dependent E-cadherin ectodomain
shedding. (a) OVCA429 and OVCA433 cells were treated with LPA
(0, 20, or 80μM, as indicated) and conditioned media evaluated
for MMP expression by gelatin zymography. (b) Cells were treated
with LPA (20μM) in the presence or absence of anti-MMP-9
function blocking antibody (10μg/mL). Conditioned media were
subjectedtoimmunoprecipitationwithanti-E-cadherinantibodies,
and precipitates were western blotted with a second E-cadherin
antibody (Zymed, 1:1,000) followed by peroxidase-conjugated
secondary antibody (1:5,000) and enhanced chemiluminescence
detection. The lower panel shows densitometric quantitation of
replicate western blots.
in E-cadherin ectodomain shedding, cells were treated with
LPA in the presence of the broad-spectrum MMP inhibitor
GM6001 (25μM). Incubation with GM6001 signiﬁcantly
reduced E-cadherin ectodomain shedding, implicating LPA-
regulated MMP activity in this process (Figures 3(a)–3(d)).
To identify whether MMP-9 may participate in LPA-induced
E-cadherin processing, cells were treated with LPA (20μM
and 80μM) for 24 hours and the resulting conditioned
media examined via gelatin zymography. An LPA dose-
dependent increase in MMP-9 expression was observed in
+GM6001
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Figure 5: Blocking MMP activity inhibits LPA-induced junction
loss. (a) OVCA429 cells were treated with LPA (30μM) for 24
hours in the presence and absence of the broad-spectrum MMP
inhibitor GM6001 (25μM) as indicated and processed for E-
cadherinimmunoﬂuorescence(green).(b)E-cadherinpositivecells
were quantiﬁed by scoring the number of cells with two remaining
borders in a minimum of 12 ﬁelds per treatment. (∗P<. 0005
relative to control; +P = .007 relative to LPA).
bothOVCA429andOVCA433cells(Figure 4(a)).Toconﬁrm
the involvement of MMP-9, cells were treated with LPA in
the presence of an anticatalytic MMP-9 function blocking
antibody. Inhibition of extracellular MMP-9 activity blocked
LPA-induced loss of cell surface E-cadherin (Figure 4(b)).
This was conﬁrmed by immunoﬂuorescence microscopy,
wherein treatment of cells with LPA in the presence of
GM6001 resulted in a signiﬁcant restoration of junctional
integrity (Figure 5(a) and 5(b)). Further, inhibition of LPA
signaling using the LPA receptor inhibitor LPARI (Ki16425;
Ki 0.3–6.5μMf o rL P A 1−3; working concentration 40μM)
[27] reduced LPA-induced MMP-9 expression and blocked
LPA-mediated junction dissolution (Figure 6).6 Journal of Oncology
+ − +L P A
− + + LPARI
(a)
L
P
A
 
(
8
0
 
µ
M
)
U
n
t
r
e
a
t
e
d
L
P
A
 
(
8
0
 
µ
M
)
+
L
P
A
R
I
L
P
A
 
(
8
0
 
µ
M
)
+
D
M
S
O
(b)
Figure 6: Inhibition of LPA receptor signaling blocks LPA-
induced E-cadherin junction loss. OVCA429 cells were treated
with LPA (80μM) for 24 hours in the presence or absence of
LPARI (20μM) or DMSO (vehicle control), as indicated. (a)
Conditionedmediawereexaminedbygelatinzymography.(b)Cells
were processed for E-cadherin immunoﬂuorescence using anti-
E-cadherin ectodomain antibody (1:300) and Alexa Fluor 488-
conjugated secondary antibody (1:500; green). Blue-DAPI-stained
nuclei.
To assess the potential functional consequence of LPA-
mediated loss of E-cadherin surface expression, epithelial
integrity was examined using a dispase-based cohesion assay
[30].ConﬂuentOVCA429orOVCA433cellmonolayerswere
treated with or without LPA for 24 hours and were then
detached from the culture dish as intact monolayers or cell
sheetsbydispasetreatment,priortoapplicationofrotational
force to compromise monolayer integrity. In response to
LPA treatment, signiﬁcantly greater fragmentation of the cell
sheet was observed compared with controls (Figure 7(a) and
7(b)) in both OVCA429 (37.4% increase, n = 6, P = 0.0203)
and OVCA433 (70% increase, n = 6, P = 0.0015). This loss
of epithelial cohesion highlights the functional relevance of
the observed loss of junctional E-cadherin.
4. Discussion
Lysophosphatic acid was originally identiﬁed as “ovarian
cancer activating factor” (OCAF) in 1995 [7]. Since its initial
discovery, LPA expression has been linked to metastatic
success in EOC through a variety of mechanisms. In EOC,
LPA signals through a diverse subfamily of G-protein-
coupled receptors (LPA1−3), to aﬀect a variety of biologic
processes including expression of extracellular proteinases
and growth factors, alteration of stress ﬁbers and focal adhe-
sion dynamics, and enhancement of motility and invasion
[12, 13, 15–17, 19, 20].
Results from the current study demonstrate a loss
of surface E-cadherin expression in response to LPA
in a dose-dependent manner. Concomitant LPA-induced
MMP-9 expression results in MMP-9-catalyzed E-cadherin
ectodomain shedding [24–28], while incubation with the
broadspectrumMMPinhibitorGM6001ortheLPAreceptor
inhibitor Ki16425 reduces shedding. As a consequence of
compromised junctional integrity, epithelial cohesion is
signiﬁcantly reduced, as evidenced by enhanced epithelial
sheet fragmentation. Loss of epithelial cohesion together
with gain of mesenchymal features is thought to accompany
mesothelial anchoring of EOC metastatic lesions [32, 33].
It was previously reported that the serine proteinase
urinary type plasminogen activator (uPA) can promote
E-cadherin ectodomain shedding following a 4-hour LPA
treatment [30], whereas inhibition of uPA activity using
a small molecule inhibitor did not block E-cadherin loss
in the current study using 24-hour LPA treatment. These
data suggest that uPA-dependent shedding may be an early
proteolytic event, while E-cadherin shedding is sustained by
subsequent expression of MMP-9. This hypothesis is sup-
ported by previous data showing additional biologic events
that promote MMP-9-dependent E-cadherin ectodomain
shedding. For example, early events in EOC intraperitoneal
metastatic dissemination involve integrin-mediated attach-
ment to the multivalent submesothelial collagen matrix
[2, 3]. Multivalent integrin engagement, in turn, induces
MMP-9-dependent E-cadherin ectodomain shedding, pro-
moting a potential mechanism for enhanced dispersal of
metastatic cells [28]. Similarly, epidermal-growth-factor-
(EGF-) induced activation of EGF receptor also potentiates
loss of surface-expressed E-cadherin. This loss of E-cadherin
expression is rescued in the presence of a broad spectrum
MMP inhibitor or by siRNA silencing of MMP-9 expression
[24].
Although elevated levels of soluble E-cadherin (sE-cad)
were identiﬁed in cancer patients nearly two decades ago
[34], the physiologic and pathophysiologic relevance of this
polypeptide fragment remains poorly understood. sE-cad
has been detected in ovarian cancer patient serum, and
evaluation of the prognostic and diagnostic value of sE-cad
serumconcentrationsisongoing[35,36].sEcadisalsohighly
prevalent in ascites ﬂuid of women with EOC, reaching
concentrations of over 12μg/mL, and addition of sEcad to
EOC cells induces characteristics of epithelial-mesenchymal
transition including junction disruption and morphologic
alteration to a migratory phenotype [28]. In contrast to
other tumors wherein shed sEcad is released into circulation,
intraperitoneally localized primary and metastatic ovarian
tumors maintain direct contact with sEcad-rich ascites. It is
interesting to speculate that loss of E-cadherin during late
metastatic progression facilitates epithelial-to-mesenchymal
transition and confers a phenotype necessary for sub-
mesothelial invasive anchoring to promote intraperitoneal
dissemination. LPA, therefore, represents a potent regulator
of key events in EOC metastasis by enhancing MMP-9-
dependent E-cadherin ectodomain shedding and promoting
motility and invasion.Journal of Oncology 7
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Figure 7: LPA treatment disrupts epithelial cohesion. Conﬂuent layers of (a) OVCA429 and (b) OVCA433 cells were treated with LPA
(40μM) for 24 hours. Cells were then detached from substratum as cell-cell adherent sheets using dispase (1mg/mL). Cohesive epithelial
sheets were transferred to tubes then subjected to 50 rotations on a bench-top rocker returned to a 60 mm culture dish, and total fragment
number was enumerated. Top panels show (a, b) OVCA429 and (c, d) OVCA433 control cells (BSA treated) as intact epithelial sheets and
cohesive multicellular strands. LPA treatment of (e, f) OVCA429 and (g, h) OVCA433 cells decreases epithelial cohesion, as evidenced by
increased fragment number enumerated in (I, J). ∗P<. 02; ∗∗P<. 002. Scale bar 1000μm.
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